Peptide Receptor Radionuclide Therapy (PRRT) Market, by Drug Type (Lutetium (Lu-177)-based), by Disease Indication (Pancreatic - Neuroendocrine Tumor, Gastrointestinal Tract - Neuroendocrine Tumor, and Others), by Distribution Channel (Hospital Pharmacies

Peptide Receptor Radionuclide Therapy (PRRT) Market, by Drug Type (Lutetium (Lu-177)-based), by Disease Indication (Pancreatic - Neuroendocrine Tumor, Gastrointestinal Tract - Neuroendocrine Tumor, and Others), by Distribution Channel (Hospital Pharmacies and Retail Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Peptide receptor radionuclide therapy (PRRT) is a molecular therapy (radioisotope therapy) used for the treatment of cancer associated with neuroendocrine tumors (NETs). In PRRT, peptides (cell targeting peptide) combine with a small amount of radioactive material to produce radiopharmaceutical product called radiopeptide. PRRT can be also considered as personalized cancer therapy, as radiopeptide can be altered into the unique biologic characteristics of the patient and the molecular properties of the tumor.
Market Dynamics
Rising number of cancer cases is a major factor driving growth of the peptide receptor radionuclide therapy (PRRT) market, globally. According to the American Cancer Society’s 2019 report, in 2021, there were an estimated 17.0 million cases of cancer diagnosed across the world and 9.5 million deaths occurred due to cancer. For instance, according to the World Health Organization’s 2021 report, cancer is the second leading cause of death globally and was responsible for an estimated 9.6 million deaths in 2021. According to the same source, globally, around 1 in 6 deaths occur due to cancer.
Approvals for PRRT is expected to boost growth of the peptide receptor radionuclide therapy (PRRT) market during the forecast period. For instance, in September 2017, Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, received approval from European Medicines Agency (EMA) for its Lutetium (177Lu) Oxodotreotide (Lutathera) drug, which is indicated for gastroenteropancreatic neuroendocrine tumor.
Key features of the study:
This report provides in-depth analysis of the global peptide receptor radionuclide therapy (PRRT) market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrixes for this market
This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles leading players in the global peptide receptor radionuclide therapy (PRRT) market based on the following parameters – company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
Key player covered as a part of this study include Novartis AG (Advanced Accelerator Applications, S.A.)
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, governmental initiatives, technological up-gradation, market expansions, and marketing tactics
The global peptide receptor radionuclide therapy (PRRT) market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers in the global peptide receptor radionuclide therapy (PRRT) industry, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Drug Type:
Lutetium (Lu-177)-based
Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Disease Indication:
Pancreatic - Neuroendocrine Tumor
Gastrointestinal Tract - Neuroendocrine Tumor
Others
Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Type:
Lutetium (Lu-177)-based
By Disease Indication:
Pancreatic - Neuroendocrine Tumor
Gastrointestinal Tract - Neuroendocrine Tumor
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Type:
Lutetium (Lu-177)-based
By Disease Indication:
Pancreatic - Neuroendocrine Tumor
Gastrointestinal Tract - Neuroendocrine Tumor
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Type:
Lutetium (Lu-177)-based
By Disease Indication:
Pancreatic - Neuroendocrine Tumor
Gastrointestinal Tract - Neuroendocrine Tumor
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Type:
Lutetium (Lu-177)-based
By Disease Indication:
Pancreatic - Neuroendocrine Tumor
Gastrointestinal Tract - Neuroendocrine Tumor
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Type:
Lutetium (Lu-177)-based
By Disease Indication:
Pancreatic - Neuroendocrine Tumor
Gastrointestinal Tract - Neuroendocrine Tumor
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Type:
Lutetium (Lu-177)-based
By Disease Indication:
Pancreatic - Neuroendocrine Tumor
Gastrointestinal Tract - Neuroendocrine Tumor
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Company Profile
Novartis AG (Advanced Accelerator Applications, S.A.)
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
“*” marked represents similar segmentation in other categories in the respective section